Following the release of peer-reviewed data, Ocuphire Pharma Inc. (NASDAQ: OCUP) shares were up 16.36% to trade at $2.49 at the time of the most recent check.
Who published the data from the OCUP?
The good outcomes in patients with night vision disturbances (NVD) from Ocuphire Pharma’s initial Phase 2 research assessing the safety and effectiveness of phentolamine mesylate eye drops (Nyxol) have been peer-reviewed and published in BMC Ophthalmology, the company reported this week.
Ocuphire Pharma’s key strengths are its high-quality clinical data and scientific communications. The distinct MOAs continue to be supported by an expanding body of scientific papers for both our front and back-of-the-eye candidates, Nyxol and APX3330, respectively. The Phase 3 LYNX-1 study in Night Vision Disturbances (NVD) was designed with the use of this Phase 2 data, and it successfully met its primary endpoint and important secondary endpoints with statistical significance. There are no available treatments for doctors, and the sole medication candidate in the development stage seeking NVD as an indication for prospective regulatory approval is Nyxol.
The clinical trial NCT04004507’s phentolamine mesylate eye drops were well tolerated, effectively reduced pupil size, and improved contrast sensitivity and visual acuity, according to a manuscript titled “A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.”
What else has OCUP declared?
Additionally, the biggest network of ophthalmic practice professionals in the eyecare industry, the American Society of Ophthalmic Administrators (ASOA), and Ocuphire Pharma (OCUP) established a strategic business partnership. The administrative staff that supports an optical practice and collaborates with the doctors is typically undervalued. In addition to doctors, OCUP thinks ophthalmic administrators are crucial to patient engagement and the success of new product acceptance. The first business to enter the recently established category for developing businesses will be Ocuphire Pharma.